ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025)
ARS Pharmaceuticals (SPRY) posted Finished Goods of $7.3 million for Q1 2025, up 39.49% sequentially from $5.2 million in Q4 2024.
ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025) Analysis & Trends
ARS Pharmaceuticals has reported Finished Goods for 2 years, with the latest figure at $7.3 million in Q1 2025.
- Quarterly Finished Goods changed N/A year-over-year to $7.3 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $7.3 million (changed N/A YoY) and the FY2024 annual result came in at $5.2 million, changed N/A from the prior year.
- Finished Goods climbed to $7.3 million in Q1 2025 per SPRY's latest filing, from $5.2 million in the prior quarter.
- Over five years, Finished Goods peaked at $7.3 million in Q1 2025 and troughed at $5.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 7.27 Mn |
| Dec 31, 2024 | 5.21 Mn |